Use of benzodiazepines in obsessive-compulsive disorder
dc.contributor.author | Starcevic, Vladan | |
dc.contributor.author | Berle, David | |
dc.contributor.author | do Rosario, Maria Conceicao [UNIFESP] | |
dc.contributor.author | Brakoulias, Vlasios | |
dc.contributor.author | Ferrao, Ygor A. | |
dc.contributor.author | Viswasam, Kirupamani | |
dc.contributor.author | Shavitt, Roseli | |
dc.contributor.author | Miguel, Euripedes | |
dc.contributor.author | Fontenelle, Leonardo F. | |
dc.date.accessioned | 2018-07-26T17:30:31Z | |
dc.date.available | 2018-07-26T17:30:31Z | |
dc.date.issued | 2016 | |
dc.description.abstract | This study aimed to determine the frequency of benzodiazepine (BDZ) use in a large sample of patients with obsessive-compulsive disorder (OCD) and ascertain the type of BDZ used and the correlates and predictors of BDZ use in OCD. The sample consisted of 955 patients with OCD from a comprehensive, cross-sectional, multicentre study conducted by the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders between 2003 and 2009. The rate of BDZ use over time in this OCD sample was 38.4%. Of individuals taking BDZs, 96.7% used them in combination with other medications, usually serotonin reuptake inhibitors. The most commonly used BDZ was clonazepam. Current age, current level of anxiety and number of additional medications for OCD taken over time significantly predicted BDZ use. This is the first study to comprehensively examine BDZ use in OCD patients, demonstrating that it is relatively common, despite recommendations from treatment guidelines. Use of BDZs in combination with several other medications over time and in patients with marked anxiety suggests that OCD patients taking BDZs may be more complex and more difficult to manage. This calls for further research and clarification of the role of BDZs in the treatment of OCD. | en |
dc.description.affiliation | Discipline of Psychiatry, Sydney Medical School – Nepean, University of Sydney, Sydney, NSW 2006, Australia | |
dc.description.affiliation | School of Psychiatry, UNSW Australia, Randwick | |
dc.description.affiliation | St John of God Health Care, Richmond Hospital, North Richmond | |
dc.description.affiliation | Department of Psychiatry, Nepean Hospital, Penrith, New South Wales, 2751, Australia | |
dc.description.affiliation | School of Psychological Sciences, Monash University, Melbourne, Victoria, 3004, Australia | |
dc.description.affiliation | Department of Psychiatry, Federal University of São Paulo, Brazil | |
dc.description.affiliation | Obsessive-Compulsive Spectrum Disorders Project, Institute and Department of Psychiatry, School of Medicine, University of São Paulo, São Paulo, Brazil | |
dc.description.affiliation | Department of Psychiatry, Federal University of Health Sciences of Porto Alegre, Rio Grande do Sul, Brazil | |
dc.description.affiliation | Anxiety and Obsessive-Compulsive Spectrum Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, D’Or Institute for Research and Education, Rio de Janeiro, Brazil | |
dc.description.affiliationUnifesp | Department of Psychiatry, Federal University of São Paulo, Brazil | |
dc.description.source | Web of Science | |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) | |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
dc.description.sponsorshipID | CNPq: 573974/2008-0 | |
dc.description.sponsorshipID | FAPESP: 2005/55628-8 | |
dc.format.extent | 27-33 | |
dc.identifier | http://dx.doi.org/10.1097/YIC.0000000000000100 | |
dc.identifier.citation | International Clinical Psychopharmacology. Philadelphia, v. 31, n. 1, p. 27-33, 2016. | |
dc.identifier.doi | 10.1097/YIC.0000000000000100 | |
dc.identifier.issn | 0268-1315 | |
dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/46095 | |
dc.identifier.wos | WOS:000366691200004 | |
dc.language.iso | eng | |
dc.publisher | Lippincott Williams & Wilkins | |
dc.relation.ispartof | International Clinical Psychopharmacology | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | anxiety | en |
dc.subject | benzodiazepines | en |
dc.subject | clonazepam | en |
dc.subject | obsessive-compulsive disorder | en |
dc.subject | treatment guidelinesPharmacological-Treatment | en |
dc.subject | Posttraumatic-Stress | en |
dc.subject | Clonazepam Treatment | en |
dc.subject | Panic Disorder | en |
dc.subject | Anxiety | en |
dc.subject | Population | en |
dc.subject | Brazil | en |
dc.subject | Clomipramine | en |
dc.subject | Guidelines | en |
dc.subject | Patterns | en |
dc.title | Use of benzodiazepines in obsessive-compulsive disorder | en |
dc.type | info:eu-repo/semantics/article |